Document is current
Any future updates will be listed below
-
Authors
Ma, Yuan-Yuan https://orcid.org/0000-0002-4545-4546
Li, Xin https://orcid.org/0000-0002-0863-6244
Yu, Zhong-Yuan
Luo, Tong
Tan, Cheng-Rong
Bai, Yu-Di
Xu, Gang
Sun, Bin-Da
Bu, Xian-Le https://orcid.org/0000-0002-2331-3339
Liu, Yu-Hui https://orcid.org/0000-0001-7320-8353
Jin, Wang-Sheng
Gao, Yu-Qi
Zhou, Xin-Fu
Liu, Juan https://orcid.org/0009-0000-2886-6701
Wang, Yan-Jiang https://orcid.org/0000-0002-6227-6112
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (92249305)
the Natural Science Foundation of Shigatse, China
High-Level Talents Innovation Project of PLA- Youth Talents of Science and Technology
- License Information
-
More Information
Article History
Received: 17 February 2024
Revised: 20 September 2024
Accepted: 25 September 2024
First Online: 3 October 2024
Competing interests
: The patent application for edaravone in the prevention and treatment of cognitive impairment induced by chronic hypobaric hypoxia is currently being prepared, Daping Hospital and Suzhou Auzone Biotech are the patent owners, and Yan-Jiang Wang, Yuan-Yuan Ma and Xin-Fu Zhou are the patent inventors. Xin-Fu Zhou is an employee of Suzhou Auzone Biotech. Other authors declare no competing interests.
